Coronary Artery Disease Therapeutics Market - Positive long-term growth outlook 2017 - 2025

Coronary artery disease (CAD) is a common type of heart disease. Coronary heart disease occurs when there is less blood flow in the arteries of the heart and the arteries get narrowed due to formation of cholesterol and plaque. Coronary artery disease leads to angina or a heart attack. Over the time, coronary artery disease can also lead to permanent heart damage, heart failure, or arrhythmias.

Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/coronary-artery-disease-therapeutics-market.html

Based on treatment type, the global coronary artery disease therapeutics market can be segmented into drugs, surgery, cardiac rehabilitation, and angioplasty. The drugs segment is likely to expand at a significant pace during the forecast period compared to other segments, due to extensive use of different classes of drugs in the treatment of coronary artery disease. Furthermore, the drugs segment can be sub-divided into beta blockers, calcium channel blockers, statin, and antiplatelet drugs. The antiplatelet drugs sub-segment is likely to expand at a high rate between 2017 and 2025, as antiplatelet drugs are highly effective in treating arterial clots that are generally composed of blood platelets. Based on test type, the coronary artery disease therapeutics market can be segmented into cardiac catheterization test, cardiac CT scan, coronary angiography, and electrocardiogram. The coronary angiography segment is expanding at a high growth rate, as the test helps the physician identify exact location of the disease in the heart and its severity. Also, the test procedure takes only 20 to 30 minutes to complete. Moreover, increasing number of Cath labs, growing obese population, rising number of smokers, and surging number of diabetes patients are factors driving the global market for coronary artery disease therapeutics. According to the World Health Organization, in 2015, almost 7.4 million people across the globe died of coronary heart diseases. However, inadequate health care facilities, drug courses with long duration, and high cost of surgery and devices (such as atherectomy device) in developing countries are restraining the coronary artery disease therapeutics market in these countries.

Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=35948

In terms of region, the global coronary artery disease therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global market. North America is projected to hold a significant share of the global market, due to increasing number of cardiovascular disease patients, improved health care facilities, and increasing geriatric population with diabetes in the region. Moreover, according to the Centers for Diseases Control & Prevention, every year, more than 735,000 people in the U.S. suffer a heart attack. Growing use of drugs, increasing adoption of different atherectomy devices for advanced health care, and rising awareness regarding the treatment of coronary artery disease are factors that boost the market in Europe. Increasing pollution, rising number of smokers, and growing prevalence of heart diseases in Asia Pacific are likely to propel the coronary artery disease therapeutics market in the region during the forecast period. The Global Cardiovascular Community states that 27.7% of the adult population in Latin America was affected with heart diseases in 2016 and the rate is increasing. This is expected to offer growth opportunities to the global coronary artery disease therapeutics market in the next few years. Advancements in surgeries, increasing per capita income, and growing incidence chronic heart diseases are likely to augment the market for coronary artery disease therapeutics in Middle East & Africa during the forecast period.

Major players operating in the global coronary artery disease therapeutics market are Astrazeneca, Gilead, Novartis, Pfizer Inc., Lupin Pharmaceuticals Inc., and Abbott Vascular.

Pre Book this Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=35948<ype=S

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact us:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.